"Viral Load" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
| Descriptor ID |
D019562
|
| MeSH Number(s) |
E01.370.225.875.950 E05.200.875.950 G06.920.850
|
| Concept/Terms |
Viral Load- Viral Load
- Load, Viral
- Viral Burden
- Burden, Viral
|
Below are MeSH descriptors whose meaning is more general than "Viral Load".
Below are MeSH descriptors whose meaning is more specific than "Viral Load".
This graph shows the total number of publications written about "Viral Load" by people in this website by year, and whether "Viral Load" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 10 | 10 |
| 2003 | 2 | 4 | 6 |
| 2004 | 0 | 8 | 8 |
| 2005 | 2 | 6 | 8 |
| 2006 | 1 | 6 | 7 |
| 2007 | 0 | 8 | 8 |
| 2008 | 0 | 6 | 6 |
| 2009 | 4 | 7 | 11 |
| 2010 | 1 | 15 | 16 |
| 2011 | 2 | 14 | 16 |
| 2012 | 2 | 12 | 14 |
| 2013 | 6 | 13 | 19 |
| 2014 | 2 | 17 | 19 |
| 2015 | 10 | 14 | 24 |
| 2016 | 3 | 19 | 22 |
| 2017 | 6 | 16 | 22 |
| 2018 | 5 | 18 | 23 |
| 2019 | 1 | 8 | 9 |
| 2020 | 4 | 14 | 18 |
| 2021 | 2 | 12 | 14 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 4 | 4 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Load" by people in Profiles.
-
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.
-
Resistance-informed versus empirical management of viraemia in children and adolescents with HIV in Lesotho and Tanzania (GIVE MOVE trial): a multisite, open-label randomised controlled trial. Lancet Glob Health. 2024 Aug; 12(8):e1312-e1322.
-
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024 May 01; 7(5):e2412835.
-
Quantitative and qualitative subgenomic RNA profiles of SARS-CoV-2 in respiratory samples: A comparison between Omicron BA.2 and non-VOC-D614G. Virol Sin. 2024 Apr; 39(2):218-227.
-
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial. J Pediatr. 2024 May; 268:113934.
-
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Cancer. 2024 03 15; 130(6):985-994.
-
Latent human herpesvirus 6 is reactivated in CAR T cells. Nature. 2023 Nov; 623(7987):608-615.
-
Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. J Infect Dis. 2023 08 11; 228(3):235-244.
-
Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19. Clin Transl Sci. 2023 06; 16(6):1049-1062.
-
Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023 Jul 01; 42(7):576-581.